What is HC Wainwright’s Estimate for IPSC Q3 Earnings?

Century Therapeutics, Inc. (NASDAQ:IPSC) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of Century Therapeutics in a report issued on Thursday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.12) per share for the quarter, down from their prior forecast of ($0.11). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Century Therapeutics’ FY2026 earnings at ($0.51) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.12) EPS and FY2027 earnings at ($0.47) EPS.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a research report on Thursday, July 2nd. Mizuho began coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price target for the company. Finally, Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.75.

Century Therapeutics Price Performance

Century Therapeutics stock opened at $1.95 on Monday. The business has a 50 day moving average of $2.19 and a 200-day moving average of $2.21. Century Therapeutics has a 1 year low of $0.43 and a 1 year high of $3.04. The company has a market capitalization of $351.68 million, a P/E ratio of -2.10 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06).

Hedge Funds Weigh In On Century Therapeutics

A number of hedge funds have recently made changes to their positions in IPSC. Seven Fleet Capital Management LP bought a new position in shares of Century Therapeutics during the second quarter worth about $10,652,174,000. Bank of America Corp DE bought a new stake in Century Therapeutics in the second quarter valued at approximately $389,000. Trails Edge Capital Partners LP bought a new stake in Century Therapeutics in the second quarter valued at approximately $10,130,674,000. Legal & General Group Plc acquired a new stake in Century Therapeutics during the 2nd quarter valued at approximately $108,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Century Therapeutics during the 2nd quarter valued at approximately $85,000. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.